2610301B20Rik Activators
2610301B20Rik activators are a diverse array of chemical compounds that indirectly enhance the functional activity of the protein through various signaling pathways and cellular processes. Forskolin, by increasing intracellular cAMP levels, activates protein kinase A (PKA), which in turn can phosphorylate key substrates and enhance the functional role of 2610301B20Rik in related signaling cascades. Similarly, the cAMP analog 8-Br-cAMP potentiates PKA signaling, thereby influencing pathways in which 2610301B20Rik may play a part, potentially altering the phosphorylation state of associated proteins. PMA, as a PKC activator, and EGCG, a kinase inhibitor, both contribute to the modulation of protein phosphorylation within pathways where 2610301B20Rik is involved, leading to enhanced activity of the protein by either stimulating or relieving inhibition of these signaling processes.
The activity of 2610301B20Rik is further influenced by compounds that modulate intracellular calcium levels, such as Ionomycin and Thapsigargin, the former being a calcium ionophore and the latter a SERCA inhibitor; both can activate calcium-dependent signaling mechanisms that may interact with or affect the function of 2610301B20Rik. Lipid signaling alterations, spurred by Sphingosine-1-phosphate, can also play a role in enhancing the activity of 2610301B20Rik by engaging with receptors that trigger downstream signaling events in which 2610301B20Rik might be implicated. Additionally, LY294002 and U0126, inhibitors of PI3K and MEK respectively, reshape the cellular signaling landscape, potentially benefiting pathways that upregulate 2610301B20Rik activity. SB203580's inhibition of p38 MAPK, 5-Azacytidine's effect on DNA methylation, and ZM 447439's influence on Aurora kinases all represent further biochemical mechanisms by which the activity of 2610301B20Rik may be enhanced, by intervening in signaling pathways and cellular processes that are either directly or indirectly related to the functional role of the protein.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $108.00 $169.00 $295.00 $561.00 $835.00 | 2 | |
8-Br-cAMP serves as a cAMP analog and activates PKA. The activation of PKA can lead to downstream effects that enhance the activity of 2610301B20Rik by altering the phosphorylation state of proteins within signaling pathways where 2610301B20Rik is involved. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which is involved in various cellular signaling processes. PKC activation can enhance the activity of 2610301B20Rik by modulating the phosphorylation of key proteins that interact with or regulate 2610301B20Rik function. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a polyphenol that inhibits certain kinase activities, potentially reducing competitive signaling and enhancing pathways in which 2610301B20Rik is functionally involved by allowing less inhibited interaction with downstream signaling proteins. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, potentially enhancing the activity of 2610301B20Rik by activating calcium-dependent signaling pathways or proteins that interact with 2610301B20Rik. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin inhibits the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to increased cytosolic calcium levels, which may enhance 2610301B20Rik activity by affecting calcium-dependent signaling pathways. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P is a bioactive lipid that can activate sphingosine-1-phosphate receptors, leading to intracellular signaling cascades that might enhance the activity of 2610301B20Rik through altered lipid signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which can alter PI3K/Akt signaling. This alteration may indirectly enhance the activity of 2610301B20Rik by modulating the interactions and activity of downstream effectors that are part of the signaling pathways involving 2610301B20Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. Inhibition of p38 MAPK may indirectly enhance the activity of 2610301B20Rik by altering the signaling dynamics within the p38 pathway, potentially affecting proteins that interact with 2610301B20Rik. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is a DNA methyltransferase inhibitor. It can lead to the hypomethylation of DNA, potentially affecting the chromatin state and accessibility of transcription factors to DNA regions that regulate the expression and activity of proteins including 2610301B20Rik. | ||||||